The Journal of Maternal-Fetal & Neonatal Medicine · 2022 · 17 citations · 17 references
Public HealthMaternal HealthObstetricsGestational DiabetesHigh-risk PregnancyReproductive EndocrinologyBlood Glucose MonitoringDiabetes MellitusGestational Diabetes MellitusMaternal ComplicationsPregnancyPregnancy EndocrinologyBiochemical Marker AssessmentCase-control Study DesignControl Group DesignMatched Control GroupPregnancy Glucose ProfilesProspective Case Study
Objective This study aimed to analyze maternal serum β-arrestin-1 and β-arrestin-2 concentrations in pregnant women complicated with gestational diabetes mellitus (GDM) and compare them with the normoglycemic uncomplicated healthy control group.Methods A prospective case-control study was conducted, including pregnant women complicated with GDM between 15 February 2021, and 31 July 2021. We recorded serum β-arrestin-1 and β-arrestin-2 concentrations of the participants. Receiver operating characteristic (ROC) curves were used to describe and compare the performance of diagnostics value of variables β-arrestin-1, and β-arrestin-2.Results The mean β-arrestin-1 and β-arrestin-2 levels were found to be significantly lower in the GDM group (41.0 ± 62.8 ng/mL, and 6.3 ± 9.9 ng/mL) than in the control group (93.1 ± 155.4 ng/mL, and 12.4 ± 17.7, respectively, p < .001). When we analyze the area under the ROC curve (AUC), maternal serum β-arrestin-1 and β-arrestin-2 levels can be considered a statistically significant parameter for diagnosing GDM. β-arrestin-1 had a significant negative correlation with fasting glucose (r = −0.551, p < .001), plasma insulin levels (r = −0.522, p < .001), HOMA-IR (r = −0.566, p < .001), and HbA1C (r = −0.465, p < .001). β-arrestin-2 was significantly negatively correlated with fasting glucose (r = −0.537, p < .001), plasma insulin levels (r = −0.515, p < .001), HOMA-IR (r = −0.550, p < .001), and HbA1C (r = −0.479, p < .001).Conclusion β-arrestin 1 and β-arrestin 2 could be utilized as biomarkers in the diagnosis of GDM. The novel therapeutic strategies targeting these β-arrestins may be designed for the GDM treatment.
17
Deficiency of a β-arrestin-2 signal complex contributes to insulin resistance
Bing Luan, Jian Zhao, Haiya Wu et al. · Nature · 2009 · 213 citations
Mechanisms in the adaptation of maternal β-cells during pregnancy
Sara Ernst, Cem Demirci, Shelley Valle et al. · Diabetes Management · 2011 · 108 citations
Stéphane Dalle, Takeshi Imamura, David W. Rose et al. · Molecular and Cellular Biology · 2002 · 76 citations · Full text